Smith, Salley & Associates Astrazeneca PLC Transaction History
Smith, Salley & Associates
- $1.35 Billion
- Q2 2024
A detailed history of Smith, Salley & Associates transactions in Astrazeneca PLC stock. As of the latest transaction made, Smith, Salley & Associates holds 15,996 shares of AZN stock, worth $1.25 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
15,996
Previous 15,828
1.06%
Holding current value
$1.25 Million
Previous $1.07 Million
16.32%
% of portfolio
0.09%
Previous 0.09%
Shares
4 transactions
Others Institutions Holding AZN
# of Institutions
1,334Shares Held
490MCall Options Held
4.99MPut Options Held
3.19M-
Price T Rowe Associates Inc Baltimore, MD64.9MShares$5.06 Billion0.61% of portfolio
-
Primecap Management CO Pasadena, CA42.6MShares$3.32 Billion2.44% of portfolio
-
Wellington Management Group LLP Boston, MA40.6MShares$3.16 Billion0.58% of portfolio
-
Capital International Investors Los Angeles, CA36.7MShares$2.86 Billion0.6% of portfolio
-
Franklin Resources Inc San Mateo, CA17.6MShares$1.37 Billion0.44% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $242B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...